Related Experiment Video

Updated: Sep 2, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

[Clinical study on cefprozil in pediatrics]

N Iwai1, M Miyazu, H Nakamura

  • 1Department of Pediatrics, Meitetsu Hospital.

The Japanese Journal of Antibiotics
|November 1, 1992
PubMed

Insights

Cefprozil (CFPZ) demonstrated high clinical and bacteriological effectiveness in pediatric infections, with a 96.4% overall efficacy rate. This oral cephalosporin showed excellent safety, with no observed side effects in children.

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacology
  • Clinical Microbiology

Background:

  • Cefprozil (CFPZ) is a novel oral cephalosporin evaluated for pediatric use.
  • Assessing clinical efficacy, bacteriological outcomes, and safety is crucial for new antibiotics.

Observation:

  • A study involved 116 pediatric patients aged 4 months to 11 years with various infections.
  • Cefprozil was administered at 4.6-14.1 mg/kg daily for 3-10 days.
  • Clinical and bacteriological data were collected from 112 patients.

Findings:

  • Cefprozil achieved a 96.4% clinical effectiveness rate across infections like pharyngitis, tonsillitis, pneumonia, and UTI.
  • Bacteriological eradication rates were 97.1% for Gram-positive and 56.8% for Gram-negative bacteria.
  • No significant side effects or ingestion refusal were noted; minor laboratory abnormalities were rare.

Implications:

  • Cefprozil is a safe and highly effective antibiotic for treating common pediatric infections.
  • Its favorable safety profile and efficacy support its use in pediatric clinical practice.
  • Further research may explore its role against resistant bacterial strains.

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...